Skip to main content
. 2023 May 4;129(1):175–182. doi: 10.1038/s41416-023-02295-x

Table 1.

Comparison of clinicopathological patient characteristics as well as TPX2 expression between the non-gemcitabine-based and the gemcitabine-based palliative treatment subgroups in the advanced PDAC cohorts.

Treatment arm, no (%)
Non-gemcitabine-based (n = 40) Gemcitabine-based (n = 99) P value (χ2)
Sex
 Female 22 (55.0) 57 (57.6) 0.78
 Male 18 (45.0) 42 (42.4)
Age (years)
 ≤60 16 (40.0) 41 (41.4) 0.88
 >60 24 (60.0) 58 (58.6)
TPX2 expression
 Low 36 (90.0) 84 (84.8) 0.42
 High 4 (10.0) 15 (15.2)
KPS
 ≤80 18 (45.0) 33 (14.9) 0.21
 >80 22 (55.0) 65 (85.1)
Grade group
 G1–G2 14 (37.5) 47 (21.2) 0.21
 G3–G4 26 (62.5) 52 (78.8)
Stage at therapy start
 Locally advanced 7 (17.5) 17 (17.2) 0.96
 Metastatic 33 (82.5) 82 (82.8)